Anticorpos monoclonais: implicações terapêuticas no câncer.

Abstract

The low selectivity of the common ways of diagnostic and treatment of neoplasias, and the fact that they constantly do not achieve the desired effects is one of the main difficulties to the oncologic pratice. Therefore, the biotecnology, with the better comprehension of the cancer biology, permitted the development of new and effetive options of biopharmaceuticals with action in specific sites in tumor cells, represent a great advancement in the medical therapeutic against the cancer. Among these new drugs, stand out the monoclonal antibodies, that nowadays represents a new therapeutic option in the treatment of tumors. The objective of this revision is to present the clinical use of the monoclonal antibodies available in the market and describe its pharmacological aspects. Currently there are a number of monoclonal antibodies approved for clinical. Of these, nine that have been used in the therepautic of the cancer were identified. They are: Panitumumab, Cetuximab, Trastuzumab, Bevacizumab, Rituximab, Gemtuzumab ozogamicina, Nimotuzumab, Alemtuzumab, Ibritumomab tiuxetano The technology for the production of recombinant monoclonal antibodies permitted to obtain less immunogenic, reducing the adverse reactions and imporoving the efficacy. Thus, appropriate combination of antibodies.